This is a working overview of Thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-27 and is reviewed periodically as new material appears.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
=== Analogues === Analogues of 6-HO-DET include diethyltryptamine (DET), 6-hydroxytryptamine (6-HT or 6-HO-T), 6-HO-DMT, 6-MeO-DMT, 6-methyl-DMT, 6-fluoro-DET, psilocin (4-HO-DMT), 4-HO-DET, bufotenin (5-HO-DMT), 7-HO-DMT, 5-HO-DET, 5-HO-DPT, and 5-HO-DiPT, among others.
Tertiary structure refers to the three-dimensional structure created by a single protein molecule (a single polypeptide chain). It may include one or several domains. The α-helices and β-pleated-sheets are folded into a compact globular structure. The folding is driven by the non-specific hydrophobic interactions, the burial of hydrophobic residues from water, but the structure is stable only when the parts of a protein domain are locked into place by specific tertiary interactions, such as salt bridges, hydrogen bonds, and the tight packing of side chains and disulfide bonds. The disulfide bonds are extremely rare in cytosolic proteins, since the cytosol (intracellular fluid) is generally a reducing environment.
Between 1978 and 1979 Channon designed and fabricated an insulin pump driven by a small compression spring with a programmable bore to allow different rates of insulin infusion. Channon tested this device on himself in what is believed to be the first time a background bolus regime was used to treat an insulin dependent diabetic. The device is now part of the Bristol Museums Collection. With the support of two National Medical Research fund (now WellChild) grants - £26,000 to Channon to fund his secondment and £40,000 to Guy's to support the clinical evaluation - Channon developed a compact insulin infusion pump "no larger than a pocket cigarette lighter" and weighing just three ounces. The pump could be set to a 3-stage decaying programme, which automatically delivered 3 infusions during the day with a successively lower dose on the 2nd and 3rd. In addition the user could manually operate the device when required to cope with the additional insulin required when eating a meal. Channon's work received national, regional and professional coverage including articles in the Times, the Telegraph, New Scientist and the bulletin of the Institute of Marine Engineers. In 1981 the work was featured in the national magazine of Diabetes UK. Following a suggestion by Professor Keen, Channon also developed a 5ml syringe with a precision engineered mechanism for delivering doses of insulin with an audible and tactile click on each rotation of a knurled thimble, for use by blind and deaf-blind diabetics.
This list contains a list of EC numbers for the first group, EC 1, oxidoreductases, placed in numerical order as determined by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. All official information is tabulated at the website of the committee. The database is developed and maintained by Andrew McDonald.
Sources: en.wikipedia.org
On July 2, 1992, John Crosbie, Canadian Federal Minister of Fisheries and Oceans, declared a two-year moratorium on the Northern Cod fishery, a designated fishing region off the coast of Newfoundland, after data showed that the total cod biomass had suffered a collapse to less than 1% of its normal value. The minister championed the measure as a temporary solution, allowing the cod population time to recover. The fisheries had long shaped the lives and communities on Canada's Atlantic eastern coast for the preceding five centuries. Societies which are dependent on fishing have a strong mutual relationship with them: the act of fishing changes the ecosystems' balance, which forces the fishery and, in turn, the fishing societies to adapt to new ecological conditions. The near-complete destruction of the Atlantic northwest cod biomass off the shores devastated coastal communities, which had been overexploiting the same cod population for decades. The fishermen along the Atlantic northwest had employed modern fishing technologies, including the ecologically devastating practice of trawling, especially in the years leading up to the 1990s, in the misguided belief that fishing stocks are perpetually plentiful and unable to be depleted. After this assumption was empirically and abruptly shown to be incorrect, to the dismay of government officials and rural workers, some 19,000 fishermen and cod processing plant workers in Newfoundland lost their employment.
) the proton lifetimes results to be far too short. To forbid these operators, a new symmetry has to be imposed: the R-parity. This symmetry also stabilizes the lightest supersymmetric particle as a dark matter candidate.
== Significance == AKH has become an important area of study, particularly in insect crop pests and insects that act as intermediate or vector hosts for parasites that can affect humans or animals . In experiments where locusts were injected with AKH and lipopolysaccharide (LPS–an immune elicitor found in the cell walls of bacteria) a stronger immune response was observed than in locusts that only received an LPS injection. The spread of malaria by the female mosquito, Anopheles gambiae, is partly dependent on the adipokinetic hormone, Anoga-HrTH (pGlu-Leu-Thr-Phe-Thr-Pro-Ala-Trp-NH2). No crystal structure of this important neuropeptide is available. The NMR restrained molecular dynamic was used to investigate its conformational space in aqueous solution and when bound to a membrane surface. The results showed that Anoga-HrTH has an almost cyclic conformation that is stabilized by a hydrogen bond between the C-terminus and Thr3. When the agonist docks to its receptor, this H-bond is broken and the molecule adopts a more extended structure. Preliminary AKHR docking calculations give the free energy of binding to be −47.30 kJ/mol. Information about the 3D structure and binding mode of Anoga-HrTH to its receptor are vital for the design of suitable mimetics which can act as insecticides.
Negros was originally called Buglas, an old Hiligaynon word thought to mean "cut off", as the island was thought to have been separated from a larger landmass. It was also known as Mamaylan and Panilougon among Cebuano-speaking Visayans. Among its earliest inhabitants were the aboriginal Ata, one of several Negrito Indigenous Peoples dispersed throughout Southeast Asia that possesses a unique culture. The westernmost portions of the island soon fell under the nominal rule of the Kedatuan of Madja-as based on the neighboring islands of Panay and Guimaras, while the eastern coasts were influenced by the Rajahnate of Cebu from the adjacent island of Cebu.
=== World War I and the American dye industry 1913 – 1930 === Through 1914, the US dye market was dominated by German imports, there were only a few small companies and German subsidiaries. With World War I, however, German dye factories now had to switch to making explosives and German shipping was cut off by British blockades. Prices quickly went up and U. S. companies built plants to meet demand. American pharmaceutical giants, even at that time, like Dow, DuPont, and others began to produce dyes and were extremely successful with simple sulphur and vat dyes. Dow Chemical developed a synthetic process for indigo in 1915, and American industry and universities worked together to reverse engineer German chemical production secrets. After the war some American munitions factories converted to dye-works, intuiting that if the reverse was possible for the German chemical industry during the war, then it ought to be feasible.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.